All In Biotech

Free tool

FAERS Monitor: Alrex

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020803 or its brand name (Alrex, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.

Reports

1,209

Serious

434

36% of reports

Hospitalization

152

Death reported

25

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain178
  • eye irritation143
  • drug ineffective108
  • off label use85
  • headache79
  • ocular hyperaemia73
  • fatigue62
  • photophobia57
  • eye swelling48
  • vision blurred48
  • lacrimation increased44
  • dry eye43
  • pain43
  • product dose omission issue42
  • condition aggravated41

Reports by year received

View as table
YearReports
20044
20058
20063
20073
200815
200912
201029
201115
201223
201315
201416
201542
201654
201746
201862
201963
202065
202188
202295
2023121
2024159
2025146
2026125

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,950 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal17855.148.19,389
photophobiaSignal5752.941.02,843
eye irritationSignal14343.337.15,872
ocular hyperaemiaSignal7326.821.51,789
lacrimation increasedSignal4425.419.01,006
eye swellingSignal4822.517.0964
dry eyeSignal4315.011.2549
vision blurredSignal486.14.6200
product dose omission issueSignal422.51.836
condition aggravatedSignal412.31.731
headacheSignal792.21.852
off label use851.71.424
drug ineffective1081.41.214
fatigue621.41.17
pain431.20.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.